J Nanobiotechnology June 2023 PMID 37328872

Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway.

Fang Cheng, Fuji Yang, Yanjin Wang, Jing Zhou, Hui Qian, Yongmin Yan

Download social card

Mentions

Peak: 2 in Jun 2023

across 2 sources since Jun 2023

Extended reach

9,852

potential audience

Total likes

Video views

Mentions per month

Jun 2023 – Sep 2023

Where it's discussed

X / Twitter4 posts
YouTube1 videos

AI synopsis

What people are saying

The discussions reflect a neutral tone, with mentions of the research methods and the publication's title, such as references to RNA-sequencing and fluorescence in situ hybridization, indicating some technical curiosity. The tone remains fairly detached, with minimal expressions of strong opinions, but a hint of recognition of the study's potential significance.

AgreementNeither agree nor disagree

Most posts acknowledge the publication but do not express strong agreement or disagreement; interest is neutral.

InterestNeutral interest

Posts mention the research topic in passing, showing moderate curiosity, but lack enthusiasm or deep analysis.

EngagementModerate engagement

There is a slight depth in engagement, such as referencing research methods like RNA-sequencing and FISH, indicating some level of technical interest.

ImpactModerate impact

Discussions imply the research could have a meaningful impact, but this is not explicitly emphasized by users.

Abstract in brief

This study shows that exosomes derived from mesenchymal stem cells (MSCex) can reduce liver fibrosis by decreasing the expression of the enzyme LOXL2, which contributes to collagen crosslinking and scarring in the liver.
The key mechanism involves miR27b-3p, a microRNA enriched in MSCex, which targets and suppresses YAP, a protein that promotes LOXL2 production, thereby reducing liver fibrosis.
The research suggests that enhancing MSCex delivery or miR27b-3p expression could be a promising new approach for treating liver fibrosis by downregulating the YAP-LOXL2 pathway.]

Read the full abstract

All mentions

MSC Exosomal miR-27b-3p Reduces Liver Fibrosis via YAP-LOXL2 Pathway

Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis by downregulating the YAP-LOXL2 pathway, reducing collagen crosslinking and scarring. This study highlights the potential of MSC exosomes as a…

STEM RTCL TV · Sep 30, 2023 45 views

Michael Buratovich

@MichaelBuratovi · X

RT @Cord_Blood_News: RNA-sequencing and fluorescence in situ hybridization (FISH

Jul 5, 2023 · 1 share · 1,172 followers View post →

Umbilical & Placental Cell News

@Cord_Blood_News · X

RNA-sequencing and fluorescence in situ hybridization (FISH

Jul 5, 2023 · 1 share · 2,035 followers View post →

Mesenchymal Cell News

@MesenchymalCell · X

Let's kick this week off with a research paper!

Jun 26, 2023 · 1 like · 1 share · 6,298 followers View post →

Hammed Onilude (PhD)

@HammedOnilude · X

Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via downregulating YAP/LOXL2 pathway https://t.co/8fmiyZoqkT

Jun 16, 2023 · 296 followers View post →